Insomnia is common in inflammatory bowel disease (IBD) and is associated with mental health conditions as well as IBD activity

Alex Barnes; Jane M Andrews; Sutapa Mukherjee; Robert V Bryant; Peter Bampton; Robert J. Fraser; Réme Mountifield

doi:10.5217/ir.2023.00028

Articles

Page Path: HOME > Intest Res > Volume 22(1); 2024 > Article

Original Article IBD Insomnia is common in inflammatory bowel disease (IBD) and is associated with mental health conditions as well as IBD activity: Alex Barnes^1,2,, Jane M Andrews^3,4, Sutapa Mukherjee^2,5, Robert V Bryant^4,6, Peter Bampton², Robert J. Fraser^1,2, Réme Mountifield^1,2; Intestinal Research 2024;22(1):104-114.
DOI: https://doi.org/10.5217/ir.2023.00028
Published online: November 1, 2023

¹Department of Gastroenterology, Southern Adelaide Local Health Network (SALHN) Flinders Medical Centre, Bedford Park, Australia

²Adelaide Institute for Sleep Health, Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, Australia

³Inflammatory Bowel Disease Service, Department of Gastroenterology and Hepatology, Central Adelaide Local Health Network (CALHN) Royal Adelaide Hospital, Adelaide, Australia

⁴School of Medicine, Faculty of Health & Medical Sciences, University of Adelaide, Adelaide, Australia

⁵Department of Respiratory and Sleep Medicine, Southern Adelaide Local Health Network (SALHN) Flinders Medical Centre, Bedford Park, Australia

⁶Department of Gastroenterology, Queen Elizabeth Hospital, Woodville, Australia

Correspondence to Alex Barnes, Flinders Medical Centre, Flinders Drive, Bedford Park, SA 5042, Australia. Tel: +61-488204-5511, Fax: +61-4882045555, E-mail: barn0255@flinders.edu.au

• Received: March 13, 2023 • Revised: July 20, 2023 • Accepted: August 22, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2,971 Views
253 Download
3 Web of Science
4 Crossref
3 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

See letter "The impact of sleep quality on the prognosis of inflammatory bowel disease commonly overlooked by gastroenterologists" in Volume 22 on page 5.

Abstract

Background/Aims
Insomnia is common in people with chronic medical conditions, such as inflammatory bowel disease (IBD), and is readily treatable through cognitive behavioral therapy for insomnia. This study aimed to describe the associations with insomnia in people with IBD and its relationship to IBD-related disability.
Methods
An online questionnaire was administered through 3 tertiary IBD centers, social media, and Crohn’s Colitis Australia. The questionnaire included the Insomnia Severity Index (ISI), a validated assessment of insomnia. Measures of anxiety, depression, physical activity, and disability were also included. IBD activity was assessed using validated patient reported scores. A multivariate model was constructed for clinically significant insomnia and ISI scores. Subpopulations of Crohn’s disease and ulcerative colitis were considered.
Results
In a cohort of 670 respondents the median age was 41 years (range, 32–70 years), with the majority female (78.4%), the majority had Crohn’s disease (57.3%). Increasingly severe disability was associated with worse insomnia score. Clinically significant insomnia was associated with clinically active IBD, abdominal pain, anxiety, and depression, in a multivariate model. In an ulcerative colitis population, Simple Clinical Colitis Activity Index components of general well-being and urgency were associated with worse ISI score in a model including depression and anxiety. In those with Crohn’s disease, the multivariate model included Harvey Bradshaw Index score in addition to depression and anxiety.
Conclusions
Insomnia is common in people with IBD and is associated with increased disability. Abdominal pain and mental health conditions should prompt consideration for screening for insomnia and referral for cognitive behavioral therapy for insomnia.
Keywords: Inflammatory bowel disease; Sleep initiation and maintenance disorders; Analgesics, opioid; Quality of life

INTRODUCTION

Sleep quality is of increased interest in inflammatory bowel disease (IBD). Abnormal sleep has been associated with several poor health incomes including cardiovascular disease [1] and all-cause mortality in some studies [2]. Meta-analyses have suggested that poor sleep is prevalent in those with IBD [3], and more common in those with clinically active IBD [4], worse than controls [5] and associated with mental health conditions [6,7] and worse quality of life [8,9]. Longitudinal studies have suggested that sleep disturbance is associated with fatigue [10], disease activity [11-13] and, in Crohn’s disease, the risk of hospitalization [14]. Insomnia is likely the most common sleep disorder in an IBD population with studies suggesting a prevalence up to 58% [8,15].

Chronic insomnia is common in those with chronic medical conditions [16-18]. This has been attributed to the effect of the symptoms associated with the disease and may exist as a symptom of the chronic medical condition itself [19]. Chronic pain is commonly seen in those with chronic insomnia with a prevalence of up to 40% [20,21]. Finally, chronic insomnia has been associated with an increased risk of cardiovascular disease [22,23] and poor outcomes such as increased hospitalisation [24] and work absenteeism [25].

Others have postulated that the symptoms of active IBD, such as nocturnal diarrhea and abdominal pain, may lead to sleep fragmentation and the development of conditioned insomnia [26]. This sleep pattern then persists following resolution of a flare and movement into an inactive IBD state. Irritable bowel syndrome-like symptoms in people with IBD may also be important with poor sleep prevalent in those with IBS [27]. Mental health conditions, such as depression and anxiety, commonly coexist with IBD and are also associated with insomnia [28].

The IBD and sleep literature has considered associations and predictors of poor sleep [13,29-34]. However there is only a single study considering IBD factors related to insomnia–noting the role of mental health conditions was not considered [15]. This study therefore aimed to explore whether there are specific disease or demographic factors associated with insomnia in an unselected IBD cohort in order to inform specific targets for an interventional study.

METHODS

An online questionnaire was made available to people with IBD via tertiary hospital patient email lists, private gastroenterology practice email lists and social media associated with a patient support organization. Individuals with a self-reported diagnosis of IBD over 18 years of age were invited to participate. Demographic data such as age and sex were recorded, along with IBD-related data including disease duration and previous surgery. Ethics approval for this study was obtained from the Southern Adelaide Human Research Ethics Committee (203.20) and informed consent was obtained from all participants.

The Insomnia Severity Index (ISI) is a self-reported questionnaire that been validated for assessment of insomnia, evaluating the response to treatment, and as an outcome measure for insomnia research [35-37]. The index consists of 7 items with a 5-point Likert scale used to rate each item. A score between 0 and 7 is considered to indicate the absence of insomnia, 8 to 14 subthreshold insomnia, 15 to 21 moderate insomnia, and over 21 denotes severe insomnia. Clinically significant insomnia is defined as an ISI score greater or equal to 10 as is commonly used in screening [35].

IBD disease activity was assessed using the Harvey Bradshaw Index (HBI) in the case of Crohn’s disease with HBI > 5 considered active disease [38]. The patient reported version of the HBI was utilized in the survey, although a decision was made to maintain the general well-being and abdominal pain score similar to the physician HBI rather than using a 10-point Likert scale [39]. The Simple Clinical Colitis Activity Index (SCCAI) was used in the case of ulcerative colitis, an SCCAI > 5 was considered active disease [40]. The patient reported form of the SCCAI was utilized in the survey [41]. The use of a self-reported SCCAI has been previously validated with good agreement with physician reported SCCAI [42]. The abdominal pain subscore from HBI was utilized to form an abdominal pain dichotomous variable with an abdominal pain subscore of mild used as the cutoff value, with values above mild encoded as one (present), and values mild or below encoded as a zero (absent). The nocturnal diarrhea subscore from SCCAI was utilized to form a nocturnal diarrhea dichotomous variable with a nocturnal diarrhea subscore of above 1 encoded as a one (present), and scores 1 or less encoded as a zero (absent).

Physical activity was assessed using the International Physical Activity Questionnaire Short Form [43]. This allows the calculation of metabolic equivalent of task values over a 1-week period of walking, moderate and vigorous activity, along with sitting time.

Anxiety was assessed using the Generalized Anxiety Disorder 7-Item Scale [44] with a score over 10 used to indicate likely clinically significant anxiety. The Patient Health Questionnaire 9 was used to assess depression with a score over 15 used to indicate likely clinically significant depression [45].

Disability was assessed using the IBD-disability index self-report (IBD-DI-SR) version [46]. The IBD-DI-SR is a validated self-reported measure of disability in an IBD population. It was developed as a self-report form and a short form of the IBD-DI [47]. The IBD-DI is considered an important endpoint for clinical trials and in clinical practice.

Statistical Analysis

Statistical analysis was performed using Stata SE 16 (StataCorp, College Station, TX, USA). Inadequate completion of score or index led to that result being discarded. For normally distributed variables mean and standard deviation were reported with comparisons made using the Student t-test. For non-normally distributed variables median, and interquartile range were reported, with comparisons made using the Mann-Whitney U test. For categorical data Pearson chi-square test was used or Fisher exact test when appropriate. One-way analysis of variance used with Tukey post-hoc test and adjusted for multiple comparisons as appropriate. A generalized linear model was also constructed for outcome of ISI score with univariate and multivariate regression performed with this optimized by the Bayesian information criterion. Logistic regression was performed for an outcome of clinically significant insomnia (ISI > 15). A multivariate logistic regression model was built for outcomes of clinically significant insomnia including demographic variables. This was model optimized by sequentially adding and removing variables to maximize the likelihood function. The margins command was used for post-estimation of probabilities. Regression was repeated for Crohn’s disease and ulcerative colitis subpopulations. Disease active scores (HBI and SCCAI) and their relationship to insomnia were examined using one-way analysis of variance used with Tukey post-hoc test and adjusted for multiple comparisons as appropriate.

RESULTS

There were 670 responses to the online questionnaire. Completion rate for the questionnaire was 90.5%. Median age was 41 years (range, 32–70 years), with most being female (78.4%), the majority had Crohn’s disease (57.3%). The mean disease duration was 11.9 ± 10.4 years, 30% had undergone surgery for IBD and around half were on biologics (50.5%) (Table 1). Clinically significant depression (Patient Health Questionnaire 9 > 15) was seen in 18%, and clinically significant anxiety (Generalized Anxiety Disorder 7-Item Scale > 10) was seen in 29%.

The median ISI score was 13 (interquartile range, 8–17). Clinically significant insomnia (ISI > 10) was seen in 62% of the cohort and over a third of the cohort had at least moderate insomnia (Table 2). A one-way analysis of variance revealed differences in disability scores (IBD-DI-SR) between insomnia severity groups (F(3,619) = 20.99, P<0.001) (Table 2), with disability scores worsening with increasing severity of insomnia. Tukey post-hoc test showed significant differences between all groups except moderate and severe insomnia groups who had similar disability scores (Supplementary Table 1).

Factors associated with an outcome of ISI score on univariate generalized linear regression included obesity, medications for sleep, opioids, current smoking status, clinically active IBD, abdominal pain, clinically significant anxiety, clinically significant depression, and methotrexate (Table 3). The parameters maintained in the optimized multivariate model included opioids, clinically active IBD, abdominal pain, clinically significant anxiety, clinically significant depression, and methotrexate. The highest coefficient was seen with clinically significant depression (3.80; 95% confidence interval, 2.68–4.93; P<0.001).

Factors associated with an outcome of clinically significant insomnia on univariate logistic regression included clinically active IBD, abdominal pain, clinically significant anxiety, and clinically significant depression (Table 4). The parameters retained in the optimized multivariate model included clinically active IBD, abdominal pain, clinically significant anxiety, and clinically significant depression. The highest odds ratio was seen with clinically significant depression (odds ratio, 3.32; 95% confidence interval, 1.89–5.83; P<0.001). The area under the receiver operator curve for the logistic regression model was 0.72.

Clinically significant insomnia was seen in 62% of the cohort. Utilizing the multivariate model for clinically significant insomnia post-estimation probabilities were calculated (Table 5). Clinically significant depression resulted in the largest increase in the probability of clinically significant insomnia (23%).

A subpopulation of ulcerative colitis was considered with all SCCAI score components significantly associated with ISI score (generalized linear regression) (Table 5). SCCAI general well-being and urgency score were included in an optimized multivariate model along with clinically significant anxiety, and clinically significant depression (Table 5). Despite abdominal pain not being part of the SCCAI this remained significantly associated with ISI score. Significant differences in mean ISI score were seen within all SCCAI component scores (Fig. 1, Supplementary Table 2). Increasing SCCAI component score was generally associated with increasing mean ISI score (Fig. 1), noting small patient numbers at the top end of SCCAI component scores. Frank blood was associated with a higher mean ISI score than no blood, with no further difference between the component scores seen.

A subpopulation of Crohn’s disease was considered. An outcome of ISI score was significant for all HBI components, except for perianal disease and oral Crohn’s disease although this was limited by small numbers (Table 6). HBI score was included in a final optimized multivariate model, along with clinically significant anxiety, and clinically significant depression. Significant differences in mean HBI were seen within all HBI component (Fig. 2, Supplementary Table 3). Differences within HBI component score groups generally suggested higher HBI component score with higher mean ISI score (Fig. 2, Supplementary Table 3), once again limited by small numbers at the top end of HBI component scores.

DISCUSSION

In a large multicenter IBD cohort, insomnia was associated with each clinically active IBD, abdominal pain, depression, and anxiety. Insomnia was prevalent with clinically significant insomnia in over 60% of the cohort, with at least a third having moderate insomnia. The prevalence of insomnia reported in this cohort is similar to that reported in rheumatology populations [48] and similar to that reported in the other IBD cohort in the literature [15]. In the general population chronic insomnia rates range from 6% to 20% [49-51].

Insomnia has a well-established association with pain [21]. In our cohort, specifically, abdominal pain was associated with insomnia. The etiology of the abdominal pain, whether related to active inflammation or irritable bowel syndrome-like symptoms, was beyond the scope of this study. It is well established that sleep deprivation is associated with hyperalgesia [52] suggesting that insomnia if present may worsen any abdominal pain. Sleep disturbances have also been linked to other gastrointestinal symptoms such as diarrhea [53]. Nocturnal diarrhea was associated with insomnia in ulcerative colitis but not in Crohn’s disease. Data on other types of pain experienced by study participants was not available. Opioid usage, acting as an indicator of chronic pain, was associated with clinically significant insomnia and worse insomnia (higher ISI scores). SCCAI components urgency and general health were included in the final multivariate model for ISI score over the inclusion of the overall SCCAI score. This may be a result of the lack of differentiation the blood SCCAI component score provided between ISI scores. SCCAI and HBI component score general well-being may in part relate to the presence of any depression, anxiety, or disability.

Insomnia has been associated with mental health conditions [54,55]. Depression and anxiety were prevalent in this population and associated with insomnia. Sleep disruption is a common presentation of mood disorders [56]. Despite treatment of the underlying mood disorder residual symptoms persist which commonly will include insomnia [28]. Treatment for insomnia is widely available in the form of cognitive behavioral therapy targeted at insomnia (CBTi) [57,58]. There has been a pilot trial of CBTi in an IBD population where it was found to be feasible and acceptable [26]. The value of CBTi in those with mood disorders is unclear and treatment is typically first directed at the underlying mood disorder [59,60]. Similarly, pain should be controlled as possible noting the relationship between sleep and hyperalgesia and acknowledging that CBTi has shown some benefit in improving pain [61]. Limitations of this study include selection bias a result of the use of an online questionnaire that may attract people with sleep problems. Similarly, the form of survey and method of recruitment is likely responsible for the predominantly female cohort. Reporting bias may also be significant, noting a study of people with Crohn’s disease reported worse sleep quality than that observed by objective measures [6]. The absence of an objective measure of IBD activity is also considered a limitation. Further studies should consider objective measures of IBD activity and sleep quality. Studies incorporating mental health interventions in those with poor sleep should be pursued. The authors also acknowledge that there are many other factors the influence insomnia that were not measured in this study.

In conclusion, insomnia is common in people with IBD with at least a third having moderate insomnia and almost two-thirds meeting criteria which warrant insomnia screening. Insomnia is associated with increased disability, clinically active IBD and depression and anxiety. Mood disorders and abdominal pain may represent insomnia treatment targets in individuals with IBD prior to consideration of CBTi.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Andrews JM, Bryant RV, and Mountifield R received speakers fees and Ad Boards from Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, BMS 2020, Celgene, Celltrion, Falk, Ferring, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Progenity, Pfizer, Sandoz, Shire, Takeda, Vifor, RAH Research Fund, The Hospital Research Fund 2020-2022, The Helmsley Trust 2020-2023. No other potential conflicts of interest relevant to this article were reported.

Data Availability Statement

Not applicable.

Author Contribution

Conceptualization: Barnes A, Andrews JM, Mukherjee S, Mountifield R. Data curation: Barnes A. Formal analysis: Barnes A. Methodology: Barnes A. Writing - original draft: Barnes A. Writing - review & editing: Barnes A, Andrews JM, Mukherjee S, Bryant RV, Bampton P, Fraser RJ. Approval of final manuscript: all authors.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Tukey Post Hoc Test for Insomnia Severity Groups^a Defined by Insomnia Severity Index Scores and Disability Scores (IBD Disability Index Self-Report Questionnaire)

ir-2023-00028-Supplementary-Table-1.pdf

Supplementary Table 2.

Results of ANOVA Analysis of ISI from the SCCAI Components

ir-2023-00028-Supplementary-Table-2.pdf

Supplementary Table 3.

Results of ANOVA Analysis of ISI from the HBI Components

ir-2023-00028-Supplementary-Table-3.pdf

Fig. 1.

Simple Clinical Colitis Activity Index score component values and mean Insomnia Severity Index scores, with standard deviation as error bars. General well-being score varies from 0: very well, 1: slightly below par, 2: poor, 3: very poor, 4: terrible. Blood score varies from 0: none, 1: trace, 2: occasionally frank, 3: usually frank. Urgency score varies from 0: no urgency, 1: hurry, 2: immediately, 3: incontinence. Nocturnal bowel motions score varies from 0: 1–3 times, 1: 4–6 times. Daytime bowel motions score varies from 0: 1–3 times, 1: 4–6 times, 2: 7–9 times, 3: >9 times. The extracolonic features score is the number of active extracolonic features.

Fig. 2.

Harvey Bradshaw Index score component values and mean Insomnia Severity Index scores, with standard deviation as error bars. General well-being score varies from 0: very well, 1: slightly below par, 2: poor, 3: very poor, 4: terrible. Liquid stool per day score varies from 0: none, 1: once, 2: twice, 3: three or more liquid bowel actions a day. Abdominal pain score varies from 0: none, 1: mild, 2: moderate, 3: severe. The extraintestinal features score is the number of active extracolonic features.

Table 1.

Demographics, IBD-Related Data, and IBD Medications

Variable	Cohort (n = 670)
Age (yr), median (IQR)	41 (32–70)
Female sex	525 (78.4)
Crohn’s disease	384 (57.3)
Disease duration (yr), mean ± SD	11.9 ± 10.4
Previous surgery for IBD	201 (30.0)
Current steroid use	58 (8.6)
Current biologic use	339 (50.5)
Current immunomodulator use	228 (34.0)
Obesity	247 (36.9)
Smoking	44 (6.6)
Alcohol usage	213 (31.8)
Opioid usage	93 (13.9)
Medications for sleep	85 (12.7)
Clinically significant depression	120 (17.9)
Clinically significant anxiety	193 (28.8)
Clinically active IBD
SCCAI, mean ± SD	7.18 ± 2.86
HBI, mean ± SD	7.08 ± 3.29
IBD-DI-SR, mean ± SD	–2.78 ± 6.01

Values are presented as number (%) unless indicated otherwise.

IBD, inflammatory bowel disease; IQR, interquartile range; SD, standard deviation; SCCAI, Simple Clinical Colitis Activity Index; HBI, Harvey Bradshaw Index; IBD-DI-SR, IBD-disability index self-report.

Table 2.

ISI Threshold Scores with Analysis of Variance Used to Demonstrate Significant Difference between Disability Scores between Groups (IBD-DI-SR)

ISI thresholds	No. (%)	IBD-DI-SR score, mean ± SD
No significant insomnia	125 (20)	–0.6 ± 4.6
Subthreshold insomnia	268 (43)	–2.6 ± 5.1
Moderate insomnia	178 (29)	–5.1 ± 6.5
Severe insomnia	52 (8)	–5.9 ± 7.4

ISI, Insomnia Severity Index; IBD-DI-SR, inflammatory bowel disease-disability index self-report; SD, standard deviation.

F(3,619)=20.99, P<0.001.

Table 3.

Generalized Linear Univariate and Multivariate Regressions for Insomnia Severity Index Score, Optimized by the Bayesian Information Criterion

	Univariate regression		Multivariate regression
	Coefficient (95% CI)	P-value	Coefficient (95% CI)	P-value
Age	–0.03 (–0.07 to 0.002)	0.062
Sex	–0.49 (–1.63 to 0.66)	0.410
Obesity	1.10 (0.12 to 2.12)	0.027
Crohn’s disease	0.23 (–0.75 to 1.21)	0.650
IBD disease duration	–0.003 (–0.05 to 0.42)	0.880
Previous surgery for IBD	–0.21 (–1.24 to 0.82)	0.690
Mediations for sleep	2.41 (1.03 to 3.79)	0.001
Corticosteroids	0.83 (–0.81 to 2.48)	0.320
Opioids	2.52 (1.20 to 3.86)	< 0.001	1.68 (0.52 to 2.85)	0.005
Biologic	–0.21 (–1.17 to 0.75)	0.660
Immunomodulators	–0.001 (–0.99 to 0.99)	0.990
Current smoker	2.08 (0.20 to 3.97)	0.030
Clinically active IBD	3.86 (2.68 to 5.03)	< 0.001	1.52 (0.42 to 2.64)	0.007
Abdominal pain	3.00 (2.07 to 3.93)	< 0.001	1.89 (1.01 to 2.76)	< 0.001
Nocturnal diarrhea	0.77 (–0.54 to 2.08)	0.250
Clinically significant anxiety	4.65 (3.74 to 5.58)	< 0.001	2.66 (1.65 to 3.67)	< 0.001
Clinically significant depression	5.46 (4.47 to 6.45)	< 0.001	3.80 (2.68 to 4.93)	< 0.001
Total METs	0.0000017 (–0.0009 to 0.0009)	0.970
Vigorous METs	–0.0001 (–0.003 to 0.0001)	0.380
Methotrexate	2.18 (0.43 to 3.94)	0.015	1.79 (0.03 to 3.29)	0.019

CI, confidence interval; IBD, inflammatory bowel disease; MET, metabolic equivalent of task.

Table 4.

Univariate and Multivariate Regression for Outcome of Clinically Significant Insomnia

	Univariate regression		Multivariate regression
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age	0.99 (0.97 to 1.00)	0.160
Sex	0.84 (0.57 to 1.24)	0.390
Obesity	1.31 (0.93 to 1.85)	0.210
Crohn’s disease	1.12 (0.81 to 1.57)	0.440
IBD disease duration	1.00 (0.99 to 1.02)	0.690
Previous surgery for IBD	0.86 (0.60 to 1.22)	0.400
Mediations for sleep	1.89 (1.12 to 3.16)	0.015
Corticosteroids	1.39 (0.78 to 2.50)	0.260
Opioids	1.92 (1.16 to 3.14)	0.010
Biologic	0.95 (0.69 to 1.31)	0.760
Immunomodulators	0.90 (0.64 to 1.26)	0.540
Current smoker	2.11 (1.01 to 4.35)	0.045
Clinically active IBD	3.04 (2.02 to 4.58)	< 0.001	1.87 (1.19 to 2.92)	0.006
Abdominal pain	2.28 (1.64 to 3.18)	< 0.001	1.84 (1.27 to 2.67)	0.001
Nocturnal diarrhea	1.10 (0.71 to 1.72)	0.650
Clinically significant anxiety	3.27 (2.26 to 4.73)	< 0.001	1.98 (1.28 to 3.08)	0.002
Clinically significant depression	4.62 (2.93 to 7.31)	< 0.001	3.32 (1.89 to 5.83)	< 0.001
Total METs	1.00 (0.99 to 1.00)	0.870
Vigorous METs	0.99 (0.99 to 1.00)	0.170
Methotrexate	3.78 (1.10 to 13.00)	0.034

This was optimized by minimizing the maximum likelihood ratio.

OR, odds ratio; CI, confidence interval; IBD, inflammatory bowel disease; MET, metabolic equivalent of task.

Table 5.

Ulcerative Colitis Population: Generalized Linear Regression for Insomnia Severity Index Score Reporting Univariate and Multivariate Regressions Optimized by the Bayesian Information Criterion

	Univariate regression		Multivariate regression
	Coefficient (95% CI)	P-value	Coefficient (95% CI)	P-value
Age	–0.02 (–0.08 to 0.04)	0.460
Sex	–0.02 (–2.20 to 1.90)	0.860
Obesity	0.25 (–1.50 to –2.00)	0.770
IBD disease duration	–0.06 (–0.15 to 0.03)	0.200
Previous surgery for IBD	–1.50 (–4.50 to 1.50)	0.330
Corticosteroids	0.70 (–1.80 to 3.30)	0.570
Opioids	4.10 (1.20 to 7.10)	0.005
Biologic	–0.50 (–2.30 to 1.20)	0.550
Immunomodulators	0.50 (–1.20 to 2.30)	0.540
5-ASA	–1.10 (–2.80 to 0.67)	0.220
Vitamin D	1.60 (–0.25 to 3.60)	0.088
Current smoker	1.20 (–2.20 to 4.70)	0.470
Clinically significant anxiety	4.90 (3.30 to 6.60)	< 0.001	2.80 (1.10 to 4.40)	0.001
Clinically significant depression	5.50 (3.60 to 7.30)	< 0.001	2.40 (0.58 to 4.30)	0.010
Any abdominal pain	3.30 (1.60 to 4.90)	< 0.001
SCCAI	0.60 (0.42 to 0.81)	< 0.001
SCCAI > 5	4.40 (2.40 to 6.40)	< 0.001
SCCAI components
No. of bowel actions during the day	1.40 (0.51 to 2.30)	0.002
No. of bowel actions during the night	6.10 (1.10 to 11.00)	0.016
Urgency	2.00 (0.92 to 3.10)	< 0.001	0.41 (–0.60 to 1.40)	0.420
Blood	1.20 (0.28 to 2.10)	0.011
General well-being	3.10 (2.30 to 3.90)	< 0.001	2.10 (1.20 to 2.90)	< 0.001
Extraintestinal manifestations	1.30 (0.60 to 2.00)	< 0.001

CI, confidence interval; IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylate based medication; SCCAI, Simple Clinical Colitis Activity Index.

Table 6.

Crohn’s Disease Population: Generalized Linear Regression for Insomnia Severity Index Score Reporting Univariate and Multivariate Regressions Optimized by the Bayesian Information Criterion

	Univariate regression		Multivariate regression
	Coefficient (95% CI)	P-value	Coefficient (95% CI)	P-value
Age	–0.004 (–0.09 to 0.66)	0.270
Sex	–0.84 (–2.40 to 0.98)	0.490
Obesity	1.70 (0.38 to 3.00)	0.011
IBD disease duration	0.17 (–0.04 to 0.08)	0.550
Previous surgery for IBD	0.01 (–0.49 to 0.07)	0.740
Corticosteroids	1.60 (–0.95 to 4.20)	0.210
Opioids	2.20 (0.45 to 3.70)	0.012
Biologic	0.34 (–0.99 to 1.70)	0.610
Immunomodulators	–0.42 (–1.70 to 0.89)	0.530
5-ASA	–0.59 (–2.50 to 1.30)	0.550
Current smoker	1.50 (–0.87 to 3.90)	0.210
Clinically significant anxiety	5.40 (4.20 to 6.70)	< 0.001	2.30 (1.00 to 3.60)	0.001
Clinically significant depression	7.80 (6.50 to 9.20)	< 0.001	4.81 (3.20 to 6.40)	< 0.001
Methotrexate	2.70 (0.50 to 4.90)	0.016
Azathioprine	–1.60 (–3.10 to –0.15)	0.048
Any abdominal pain	3.90 (2.60 to 5.10)	< 0.001
Any nocturnal bowel actions	5.80 (–1.00 to 12.60)	0.096
HBI	0.54 (0.39 to 0.69)	< 0.001	0.58 (0.40 to 0.77)	< 0.001
HBI > 5	4.80 (3.60 to 6.10)	< 0.001
HBI components
General well-being	2.90 (2.30 to 3.60)	< 0.001
Abdominal pain	2.50 (1.80 to 3.30)	< 0.001
Number of liquid/soft stool	1.20 (0.50 to 1.90)	< 0.001
Active arthropathy	3.30 (2.10 to 4.60)	< 0.001
Ocular manifestations	3.00 (1.80 to 4.30)	< 0.001
Skin manifestations	1.80 (0.16 to 3.50)	0.031
Active perianal disease	1.00 (–0.52 to 2.60)	0.190
Oral manifestations	1.40 (–0.05 to –2.90)	0.058
Number of extraintestinal manifestations	1.50 (0.99 to 2.00)	< 0.001

CI, confidence interval; IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylate based medication; HBI, Harvey Bradshaw Index.

REFERENCES

1. Daghlas I, Dashti HS, Lane J, et al. Sleep duration and myocardial infarction. J Am Coll Cardiol 2019;74:1304–1314.Article PubMed PMC
2. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep 2010;33:585–592.Article PubMed PMC
3. Barnes A, Mountifield R, Baker J, et al. A systematic review and meta-analysis of the prevalence of poor sleep in inflammatory bowel disease. Sleep Adv 2022;3:zpac025.Article PubMed PMC PDF
4. Ballesio A, Zagaria A, Baccini F, Micheli F, Di Nardo G, Lombardo C. A meta-analysis on sleep quality in inflammatory bowel disease. Sleep Med Rev 2021;60:101518.Article PubMed
5. Hao G, Zhu B, Li Y, Wang P, Li L, Hou L. Sleep quality and disease activity in patients with inflammatory bowel disease: a systematic review and meta-analysis. Sleep Med 2020;75:301–308.Article PubMed
6. Iskandar HN, Linan EE, Patel A, et al. Self-reported sleep disturbance in Crohn’s disease is not confirmed by objective sleep measures. Sci Rep 2020;10:1980.Article PubMed PMC PDF
7. Gîlc-Blanariu GE, Ștefnescu G, Trifan AV, et al. Sleep impairment and psychological distress among patients with inflammatory bowel disease-beyond the obvious. J Clin Med 2020;9:2304.Article PubMed PMC
8. Scott AJ, Flowers O, Rowse G. Do specific types of sleep disturbances represent risk factors for poorer health-related quality of life in inflammatory bowel disease? A longitudinal cohort study. Br J Health Psychol 2021;26:90–108.Article PubMed PDF
9. Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses. Part I. Inflamm Bowel Dis 2018;24:742–751.Article PubMed
10. Graff LA, Vincent N, Walker JR, et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1882–1889.Article PubMed
11. Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013;11:965–971.Article PubMed PMC
12. Kappelman MD, Long MD, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:1315–23.e2.Article PubMed PMC
13. Uemura R, Fujiwara Y, Iwakura N, et al. Sleep disturbances in Japanese patients with inflammatory bowel disease and their impact on disease flare. Springerplus 2016;5:1792.Article PubMed PMC PDF
14. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Sleep duration affects risk for ulcerative colitis: a prospective cohort study. Clin Gastroenterol Hepatol 2014;12:1879–1886.Article PubMed PMC
15. Salwen-Deremer JK, Smith MT, Haskell HG, Schreyer C, Siegel CA. Poor sleep in inflammatory bowel disease is reflective of distinct sleep disorders. Dig Dis Sci 2022;67:3096–3107.Article PubMed PDF
16. Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30:213–218.Article PubMed
17. Koyanagi A, Garin N, Olaya B, et al. Chronic conditions and sleep problems among adults aged 50 years or over in nine countries: a multi-country study. PLoS One 2014;9:e114742.Article PubMed PMC
18. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158:1099–1107.Article PubMed
19. Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006;12:S221–S229.PubMed
20. Tang NK, Wright KJ, Salkovskis PM. Prevalence and correlates of clinical insomnia co-occurring with chronic back pain. J Sleep Res 2007;16:85–95.Article PubMed
21. Ohayon MM. Relationship between chronic painful physical condition and insomnia. J Psychiatr Res 2005;39:151–159.Article PubMed
22. Schwartz S, McDowell Anderson W, Cole SR, Cornoni-Huntley J, Hays JC, Blazer D. Insomnia and heart disease: a review of epidemiologic studies. J Psychosom Res 1999;47:313–333.PubMed
23. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med 2002;251:207–216.Article PubMed
24. Novak M, Mucsi I, Shapiro CM, Rethelyi J, Kopp MS. Increased utilization of health services by insomniacs: an epidemiological perspective. J Psychosom Res 2004;56:527–536.Article PubMed
25. Léger D, Massuel MA, Metlaine A, SISYPHE Study Group. Professional correlates of insomnia. Sleep 2006;29:171–178.PubMed
26. Salwen-Deremer JK, Smith MT, Aschbrenner KA, Haskell HG, Speed BC, Siegel CA. A pilot feasibility trial of cognitive-behavioural therapy for insomnia in people with inflammatory bowel disease. BMJ Open Gastroenterol 2021;8:e000805.Article PubMed PMC
27. Wang B, Duan R, Duan L. Prevalence of sleep disorder in irritable bowel syndrome: a systematic review with meta-analysis. Saudi J Gastroenterol 2018;24:141–150.Article PubMed PMC
28. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011;31:180–186.Article PubMed PMC
29. Frigstad SO, Høivik ML, Jahnsen J, et al. Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients. World J Gastroenterol 2018;24:3293–3301.Article PubMed PMC
30. Gingold-Belfer R, Peled N, Levy S, et al. Impaired sleep quality in Crohn’s disease depends on disease activity. Dig Dis Sci 2014;59:146–151.Article PubMed PDF
31. Marinelli C, Savarino EV, Marsilio I, et al. Sleep disturbance in inflammatory bowel disease: prevalence and risk factors: a cross-sectional study. Sci Rep 2020;10:507.Article PubMed PMC PDF
32. Keskin EB, Şahbaz CD. Chronotype and sleep quality in patients with inflammatory bowel disease. Med Bull Haseki 2020;58:72–77.Article
33. Sochal M, Małecka-Panas E, Gabryelska A, et al. Determinants of sleep quality in inflammatory bowel diseases. J Clin Med 2020;9:2921.Article PubMed PMC
34. Sofia MA, Lipowska AM, Zmeter N, Perez E, Kavitt R, Rubin DT. Poor sleep quality in Crohn’s disease is associated with disease activity and risk for hospitalization or surgery. Inflamm Bowel Dis 2020;26:1251–1259.Article PubMed PMC PDF
35. Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 2011;34:601–608.Article PubMed PMC
36. Blais FC, Gendron L, Mimeault V, Morin CM. Evaluation of insomnia: validity of 3 questionnaires. Encephale 1997;23:447–453.PubMed
37. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297–307.Article PubMed
38. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514.Article PubMed
39. Bennebroek Evertsz’ F, Hoeks CC, Nieuwkerk PT, et al. Development of the patient Harvey Bradshaw Index and a comparison with a clinician-based Harvey Bradshaw Index assessment of Crohn’s disease activity. J Clin Gastroenterol 2013;47:850–856.Article PubMed
40. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29–32.Article PubMed PMC
41. Bennebroek Evertsz’ F, Nieuwkerk PT, Stokkers PC, et al. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis 2013;7:890–900.Article PubMed
42. Marín-Jiménez I, Nos P, Domènech E, et al. Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study. Am J Gastroenterol 2016;111:261–268.Article PubMed PDF
43. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381–1395.Article PubMed
44. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–1097.Article PubMed
45. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–613.Article PubMed PMC
46. Paulides E, Kim C, Frampton C, et al. Validation of the inflammatory bowel disease disability index for self-report and development of an item-reduced version. J Gastroenterol Hepatol 2019;34:92–102.Article PubMed PDF
47. Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut 2017;66:588–596.Article PubMed
48. Mustafa M, Bawazir Y, Merdad L, et al. Frequency of sleep disorders in patients with rheumatoid arthritis. Open Access Rheumatol 2019;11:163–171.PubMed PMC
49. Reynolds AC, Appleton SL, Gill TK, Adams RJ. Chronic insomnia disorder in Australia. Sleep Health Foundation, North Strathfield: 2019.
50. Sivertsen B, Pallesen S, Friborg O, et al. Sleep patterns and insomnia in a large population-based study of middle-aged and older adults: the Tromsø study 2015-2016. J Sleep Res 2021;30:e13095.Article PubMed PDF
51. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111.Article PubMed
52. Schuh-Hofer S, Wodarski R, Pfau DB, et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: a surrogate pain model to study the relationship of insomnia and pain. Pain 2013;154:1613–1621.Article PubMed
53. Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ. Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population. Neurogastroenterol Motil 2009;21:128–135.Article PubMed PMC
54. Ellis JG, Perlis ML, Bastien CH, Gardani M, Espie CA. The natural history of insomnia: acute insomnia and first-onset depression. Sleep 2014;37:97–106.Article PubMed PMC
55. Cox RC, Olatunji BO. Sleep in the anxiety-related disorders: a meta-analysis of subjective and objective research. Sleep Med Rev 2020;51:101282.Article PubMed
56. Sylvia LG, Dupuy JM, Ostacher MJ, et al. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol 2012;26:1108–1112.Article PubMed PMC PDF
57. van der Zweerde T, Bisdounis L, Kyle SD, Lancee J, van Straten A. Cognitive behavioral therapy for insomnia: a meta-analysis of long-term effects in controlled studies. Sleep Med Rev 2019;48:101208.Article PubMed
58. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 2015;163:191–204.Article PubMed
59. Sadler P, McLaren S, Klein B, Harvey J, Jenkins M. Cognitive behavior therapy for older adults with insomnia and depression: a randomized controlled trial in community mental health services. Sleep 2018;41:zsy104.Article
60. Manber R, Buysse DJ, Edinger J, et al. Efficacy of cognitive-behavioral therapy for insomnia combined with antidepressant pharmacotherapy in patients with comorbid depression and insomnia: a randomized controlled trial. J Clin Psychiatry 2016;77:e1316–e1323.Article PubMed
61. McCurry SM, Zhu W, Von Korff M, et al. Effect of telephone cognitive behavioral therapy for insomnia in older adults with osteoarthritis pain: a randomized clinical trial. JAMA Intern Med 2021;181:530–538.Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

The impact of sleep quality on the prognosis of inflammatory bowel disease commonly overlooked by gastroenterologists
Ji Young Chang
Intestinal Research.2024; 22(1): 5. CrossRef
Sleep quality is associated with reduced quality of life in inflammatory bowel disease through its interaction with pain
Alex Barnes, Robert V Bryant, Sutapa Mukherjee, Paul Spizzo, Réme Mountifield
JGH Open.2024;[Epub] CrossRef
The IBD Clinic of Tomorrow: Holistic, Patient-Centric, and Value-based Care
Benjamin Click, Raymond K. Cross, Miguel Regueiro, Laurie Keefer
Clinical Gastroenterology and Hepatology.2024;[Epub] CrossRef
Chronic Poor Sleep is Associated with Increased Disease Activity in Patients with Ulcerative Colitis: Prospective Observational Study in Japan
Hideaki Oyama, Rintaro Moroi, Atsushi Sakuma, Yusuke Shimoyama, Hiroshi Nagai, Takeo Naito, Hisashi Shiga, Yoichi Kakuta, Yoshitaka Kinouchi, Atsushi Masamune
Journal of Crohn's and Colitis.2024;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Insomnia is common in inflammatory bowel disease (IBD) and is associated with mental health conditions as well as IBD activity

Intest Res. 2024;22(1):104-114. Published online November 1, 2023

DOI: https://doi.org/10.5217/ir.2023.00028

XML Download

Figure

Insomnia is common in inflammatory bowel disease (IBD) and is associated with mental health conditions as well as IBD activity

Fig. 1. Simple Clinical Colitis Activity Index score component values and mean Insomnia Severity Index scores, with standard deviation as error bars. General well-being score varies from 0: very well, 1: slightly below par, 2: poor, 3: very poor, 4: terrible. Blood score varies from 0: none, 1: trace, 2: occasionally frank, 3: usually frank. Urgency score varies from 0: no urgency, 1: hurry, 2: immediately, 3: incontinence. Nocturnal bowel motions score varies from 0: 1–3 times, 1: 4–6 times. Daytime bowel motions score varies from 0: 1–3 times, 1: 4–6 times, 2: 7–9 times, 3: >9 times. The extracolonic features score is the number of active extracolonic features.

Fig. 2. Harvey Bradshaw Index score component values and mean Insomnia Severity Index scores, with standard deviation as error bars. General well-being score varies from 0: very well, 1: slightly below par, 2: poor, 3: very poor, 4: terrible. Liquid stool per day score varies from 0: none, 1: once, 2: twice, 3: three or more liquid bowel actions a day. Abdominal pain score varies from 0: none, 1: mild, 2: moderate, 3: severe. The extraintestinal features score is the number of active extracolonic features.

Fig. 1.

Fig. 2.

Insomnia is common in inflammatory bowel disease (IBD) and is associated with mental health conditions as well as IBD activity

Variable	Cohort (n = 670)
Age (yr), median (IQR)	41 (32–70)
Female sex	525 (78.4)
Crohn’s disease	384 (57.3)
Disease duration (yr), mean ± SD	11.9 ± 10.4
Previous surgery for IBD	201 (30.0)
Current steroid use	58 (8.6)
Current biologic use	339 (50.5)
Current immunomodulator use	228 (34.0)
Obesity	247 (36.9)
Smoking	44 (6.6)
Alcohol usage	213 (31.8)
Opioid usage	93 (13.9)
Medications for sleep	85 (12.7)
Clinically significant depression	120 (17.9)
Clinically significant anxiety	193 (28.8)
Clinically active IBD
SCCAI, mean ± SD	7.18 ± 2.86
HBI, mean ± SD	7.08 ± 3.29
IBD-DI-SR, mean ± SD	–2.78 ± 6.01

ISI thresholds	No. (%)	IBD-DI-SR score, mean ± SD
No significant insomnia	125 (20)	–0.6 ± 4.6
Subthreshold insomnia	268 (43)	–2.6 ± 5.1
Moderate insomnia	178 (29)	–5.1 ± 6.5
Severe insomnia	52 (8)	–5.9 ± 7.4

	Univariate regression		Multivariate regression
	Coefficient (95% CI)	P-value	Coefficient (95% CI)	P-value
Age	–0.03 (–0.07 to 0.002)	0.062
Sex	–0.49 (–1.63 to 0.66)	0.410
Obesity	1.10 (0.12 to 2.12)	0.027
Crohn’s disease	0.23 (–0.75 to 1.21)	0.650
IBD disease duration	–0.003 (–0.05 to 0.42)	0.880
Previous surgery for IBD	–0.21 (–1.24 to 0.82)	0.690
Mediations for sleep	2.41 (1.03 to 3.79)	0.001
Corticosteroids	0.83 (–0.81 to 2.48)	0.320
Opioids	2.52 (1.20 to 3.86)	< 0.001	1.68 (0.52 to 2.85)	0.005
Biologic	–0.21 (–1.17 to 0.75)	0.660
Immunomodulators	–0.001 (–0.99 to 0.99)	0.990
Current smoker	2.08 (0.20 to 3.97)	0.030
Clinically active IBD	3.86 (2.68 to 5.03)	< 0.001	1.52 (0.42 to 2.64)	0.007
Abdominal pain	3.00 (2.07 to 3.93)	< 0.001	1.89 (1.01 to 2.76)	< 0.001
Nocturnal diarrhea	0.77 (–0.54 to 2.08)	0.250
Clinically significant anxiety	4.65 (3.74 to 5.58)	< 0.001	2.66 (1.65 to 3.67)	< 0.001
Clinically significant depression	5.46 (4.47 to 6.45)	< 0.001	3.80 (2.68 to 4.93)	< 0.001
Total METs	0.0000017 (–0.0009 to 0.0009)	0.970
Vigorous METs	–0.0001 (–0.003 to 0.0001)	0.380
Methotrexate	2.18 (0.43 to 3.94)	0.015	1.79 (0.03 to 3.29)	0.019

	Univariate regression		Multivariate regression
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age	0.99 (0.97 to 1.00)	0.160
Sex	0.84 (0.57 to 1.24)	0.390
Obesity	1.31 (0.93 to 1.85)	0.210
Crohn’s disease	1.12 (0.81 to 1.57)	0.440
IBD disease duration	1.00 (0.99 to 1.02)	0.690
Previous surgery for IBD	0.86 (0.60 to 1.22)	0.400
Mediations for sleep	1.89 (1.12 to 3.16)	0.015
Corticosteroids	1.39 (0.78 to 2.50)	0.260
Opioids	1.92 (1.16 to 3.14)	0.010
Biologic	0.95 (0.69 to 1.31)	0.760
Immunomodulators	0.90 (0.64 to 1.26)	0.540
Current smoker	2.11 (1.01 to 4.35)	0.045
Clinically active IBD	3.04 (2.02 to 4.58)	< 0.001	1.87 (1.19 to 2.92)	0.006
Abdominal pain	2.28 (1.64 to 3.18)	< 0.001	1.84 (1.27 to 2.67)	0.001
Nocturnal diarrhea	1.10 (0.71 to 1.72)	0.650
Clinically significant anxiety	3.27 (2.26 to 4.73)	< 0.001	1.98 (1.28 to 3.08)	0.002
Clinically significant depression	4.62 (2.93 to 7.31)	< 0.001	3.32 (1.89 to 5.83)	< 0.001
Total METs	1.00 (0.99 to 1.00)	0.870
Vigorous METs	0.99 (0.99 to 1.00)	0.170
Methotrexate	3.78 (1.10 to 13.00)	0.034

	Univariate regression		Multivariate regression
	Coefficient (95% CI)	P-value	Coefficient (95% CI)	P-value
Age	–0.02 (–0.08 to 0.04)	0.460
Sex	–0.02 (–2.20 to 1.90)	0.860
Obesity	0.25 (–1.50 to –2.00)	0.770
IBD disease duration	–0.06 (–0.15 to 0.03)	0.200
Previous surgery for IBD	–1.50 (–4.50 to 1.50)	0.330
Corticosteroids	0.70 (–1.80 to 3.30)	0.570
Opioids	4.10 (1.20 to 7.10)	0.005
Biologic	–0.50 (–2.30 to 1.20)	0.550
Immunomodulators	0.50 (–1.20 to 2.30)	0.540
5-ASA	–1.10 (–2.80 to 0.67)	0.220
Vitamin D	1.60 (–0.25 to 3.60)	0.088
Current smoker	1.20 (–2.20 to 4.70)	0.470
Clinically significant anxiety	4.90 (3.30 to 6.60)	< 0.001	2.80 (1.10 to 4.40)	0.001
Clinically significant depression	5.50 (3.60 to 7.30)	< 0.001	2.40 (0.58 to 4.30)	0.010
Any abdominal pain	3.30 (1.60 to 4.90)	< 0.001
SCCAI	0.60 (0.42 to 0.81)	< 0.001
SCCAI > 5	4.40 (2.40 to 6.40)	< 0.001
SCCAI components
No. of bowel actions during the day	1.40 (0.51 to 2.30)	0.002
No. of bowel actions during the night	6.10 (1.10 to 11.00)	0.016
Urgency	2.00 (0.92 to 3.10)	< 0.001	0.41 (–0.60 to 1.40)	0.420
Blood	1.20 (0.28 to 2.10)	0.011
General well-being	3.10 (2.30 to 3.90)	< 0.001	2.10 (1.20 to 2.90)	< 0.001
Extraintestinal manifestations	1.30 (0.60 to 2.00)	< 0.001

	Univariate regression		Multivariate regression
	Coefficient (95% CI)	P-value	Coefficient (95% CI)	P-value
Age	–0.004 (–0.09 to 0.66)	0.270
Sex	–0.84 (–2.40 to 0.98)	0.490
Obesity	1.70 (0.38 to 3.00)	0.011
IBD disease duration	0.17 (–0.04 to 0.08)	0.550
Previous surgery for IBD	0.01 (–0.49 to 0.07)	0.740
Corticosteroids	1.60 (–0.95 to 4.20)	0.210
Opioids	2.20 (0.45 to 3.70)	0.012
Biologic	0.34 (–0.99 to 1.70)	0.610
Immunomodulators	–0.42 (–1.70 to 0.89)	0.530
5-ASA	–0.59 (–2.50 to 1.30)	0.550
Current smoker	1.50 (–0.87 to 3.90)	0.210
Clinically significant anxiety	5.40 (4.20 to 6.70)	< 0.001	2.30 (1.00 to 3.60)	0.001
Clinically significant depression	7.80 (6.50 to 9.20)	< 0.001	4.81 (3.20 to 6.40)	< 0.001
Methotrexate	2.70 (0.50 to 4.90)	0.016
Azathioprine	–1.60 (–3.10 to –0.15)	0.048
Any abdominal pain	3.90 (2.60 to 5.10)	< 0.001
Any nocturnal bowel actions	5.80 (–1.00 to 12.60)	0.096
HBI	0.54 (0.39 to 0.69)	< 0.001	0.58 (0.40 to 0.77)	< 0.001
HBI > 5	4.80 (3.60 to 6.10)	< 0.001
HBI components
General well-being	2.90 (2.30 to 3.60)	< 0.001
Abdominal pain	2.50 (1.80 to 3.30)	< 0.001
Number of liquid/soft stool	1.20 (0.50 to 1.90)	< 0.001
Active arthropathy	3.30 (2.10 to 4.60)	< 0.001
Ocular manifestations	3.00 (1.80 to 4.30)	< 0.001
Skin manifestations	1.80 (0.16 to 3.50)	0.031
Active perianal disease	1.00 (–0.52 to 2.60)	0.190
Oral manifestations	1.40 (–0.05 to –2.90)	0.058
Number of extraintestinal manifestations	1.50 (0.99 to 2.00)	< 0.001

Table 1. Demographics, IBD-Related Data, and IBD Medications

Values are presented as number (%) unless indicated otherwise.

Table 2. ISI Threshold Scores with Analysis of Variance Used to Demonstrate Significant Difference between Disability Scores between Groups (IBD-DI-SR)

ISI, Insomnia Severity Index; IBD-DI-SR, inflammatory bowel disease-disability index self-report; SD, standard deviation.

F(3,619)=20.99, P<0.001.

Table 3. Generalized Linear Univariate and Multivariate Regressions for Insomnia Severity Index Score, Optimized by the Bayesian Information Criterion

CI, confidence interval; IBD, inflammatory bowel disease; MET, metabolic equivalent of task.

Table 4. Univariate and Multivariate Regression for Outcome of Clinically Significant Insomnia

This was optimized by minimizing the maximum likelihood ratio.

OR, odds ratio; CI, confidence interval; IBD, inflammatory bowel disease; MET, metabolic equivalent of task.

Table 5. Ulcerative Colitis Population: Generalized Linear Regression for Insomnia Severity Index Score Reporting Univariate and Multivariate Regressions Optimized by the Bayesian Information Criterion

CI, confidence interval; IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylate based medication; SCCAI, Simple Clinical Colitis Activity Index.

Table 6. Crohn’s Disease Population: Generalized Linear Regression for Insomnia Severity Index Score Reporting Univariate and Multivariate Regressions Optimized by the Bayesian Information Criterion

CI, confidence interval; IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylate based medication; HBI, Harvey Bradshaw Index.